

DELPHI SURVEYS

Towards Core Outcome Sets for Blood Cancers

AIM

Identify minimum set of outcomes (=core outcome set, COS) to be measured in future clinical trials, agreed upon by HARMONY's stakeholder groups.

FIRST
for individual disease

LATER
COS applicable to multiple blood cancers

MULTIPLE SURVEYS

Acute Myeloid Leukemia

AML

Non-Hodgkin Lymphoma

NHL

Multiple Myeloma

MM

Myelodysplastic Syndromes

MDS

Chronic Lymphocytic Leukemia

CLL

Acute Lymphoblastic Leukemia

ALL

More

...



WHY

Enhance comparability future clinical trials

Improve clinical management

Guide collection of registry & real-world data

4 STAKEHOLDER GROUPS

Patients

Clinicians

Drug developers
Members of the European Federation of Pharmaceutical Industries and Associations

Regulators

DELPHI METHOD

STEP 1

Create preliminary list of ~70 outcomes

based on literature research & expert interviews, e.g. overall survival, intensive unit admissions

STEPS 2-4

3 iterative survey rounds

Panel of stakeholders rate importance of outcomes

STEP 5

Final consensus meeting

Discuss and reaffirm COS